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Abstract
Background: Poor medication adherence is a major factor in the secondary prevention of cardiovascular diseases
(CVD) and contributes to increased morbidity, mortality, and costs. Interventions for improving medication
adherence may have limited effects as a consequence of self selection of already highly adherent participants into
clinical trials.
Methods: In this retrospective cohort study, existing levels of medication adherence were examined in self-decided
participants and non-participants prior to inclusion in a randomized controlled study (RCT), evaluating the effect of
an intervention to improve adherence. In addition, the non-participants were further divided into ‘responders’ and
‘non responders’. All individuals had manifest cardiovascular disease and completed a questionnaire with baseline
characteristics, the Beliefs about Medicines Questionnaire (BMQ) and the Modified Morisky Scale® (MMS®) as part of
a regular screening program. A logistic regression was conducted to examine the relationship between study
participation willingness, adherence level and the beliefs about medication.
Results: According to the MMS® the adherence level was comparable in all groups. In both (non)-participants
groups, 36% was classified as high adherent; 46% participants versus 44% non-participants were classified as
medium adherent and 19% of the participants versus 20% of the non-participants were low adherent (p = 0.91. The
necessity concern differential (NCD) from the BMQ was 3.8 for participants and 3.4 for non-participants (p = 0.32).
Conclusion: This study shows that adherence to medication and beliefs about medication do not differ between
participants and non-participants before consenting to participate in an RCT. The study design seems not to have
led to greater adherence in the study group.
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Background
Cardiovascular risk reduction is predominantly based
on lipid and blood pressure lowering treatment, in-
hibition of platelet aggregation, smoking cessation
and control of obesity [1]. A limitation in lowering
cardiovascular risk is poor adherence to prescribed
medication [2] which may consequently can lead to
increased morbidity, mortality and costs [3–6]. Never-
theless, a recent review with mostly cohort studies,
showed that only 60% of people who use cardiovascu-
lar medication, were adherent to their cardiovascular
medication [7]. In view of that there is a need for in-
terventions to improve medication adherence in this
population. Although there is a considerable amount
of research in the field of interventions to improve
medication adherence in cardiovascular patients, they
often show only small effects [8]. It is suggested that
patient recruitment methods in randomized con-
trolled trials (RCT) to improve patient adherence to
medication may influence outcome [8, 9]. An import-
ant observation is that patients participating in RCTs
generally have higher adherence rates at baseline than
could be expected based on observational studies
[10–14]. It is conceivable that the informed consent
procedure results in a selection of patients with
higher adherence rates [12]. Willingness to participate
is positively influenced by patients’ engagement with
their medical condition, high level of education and
the influence of an important person [11, 15]. These
characteristics are also considered as positive determi-
nants for medication adherence [16]. Although a re-
cent review showed that the inclusion of non
adherent patients was the single feature significantly
associated with effective adherence interventions, most
studies seem to include patients because they are willing
to participate not because they are poor adherent [11]. It
is suggested that patients participating in these RCTs
already have a pre-existing high adherence level at base-
line [10, 12–14]. Selection of participants with high levels
of adherence at baseline, makes it difficult to show an im-
proving intervention effect (ceiling effect) [8]. More un-
derstanding about the medication adherence of
participants as well as non-participants before the start of
these RCT’s may contribute to a better understanding of
why so many studies show no improvement in medi-
cation adherence. One possible explanatory determin-
ant for (non) adherent behaviour is medication
beliefs. Personal beliefs about need for treatment (ne-
cessity beliefs) and concerns about several potential
adverse consequences (concern beliefs) could explain
a large part of (non) adherent behaviour [16–18]. If
patients perceive that the need for medication
outweighs the concerns, they are more likely to be
adherent to their medication(s) [19].
Methods
Aim
The aim of this study is to explore possible differences
in adherence to existing prescribed medication in car-
diovascular patients who did or did not consent to par-
ticipate in an RCT which expressly explored the effects
of an intervention to improve adherence. We hypothe-
sized that patients who are willing to participate in a
clinical trial are more likely to be medication adherent
and have more ‘necessity beliefs’ about their medication
compared to patients who are not willing to participate.
Study design and setting
In this retrospective cohort study we included patients
who participated or declined participation in the (MIR-
ROR) trial (a Multifaceted nurse -and web-based Inter-
vention for impRoving adheRence to treatment in patients
with cardiOvasculaR disease) [20]. In brief, the MIRROR
trial was a prospective, randomized controlled trial in
which patients aged ≥18 years and diagnosed with a mani-
fest cardiovascular disease (i.e. acute coronary syndrome,
peripheral arterial disease or stroke/Transient Ischemic
Attack (TIA)) after providing written informed consent,
were included. The MIRROR trial aimed to study the ef-
fect of different adherence enhancing strategies on cardio-
vascular medication adherence. Within this context,
patients were randomized to usual care, an e-health inter-
vention, and an e-health intervention combined with mo-
tivational technique consultations.
Participants
All patients referred to the Radboud University Medical
Center with a new diagnosis of acute coronary syn-
drome, myocardial infarction, peripheral arterial disease,
an aneurysm of the aorta or TIA or stroke over the prior
6 weeks were included into the hospital CVD screening
program. This screening program aims to identify car-
diovascular risk factors and consists of screening for life-
style (smoking, diet and exercise), medication adherence
by the self reported questionnaires Modified Morisky
Scale® (MMS®) and the Beliefs about Medication Ques-
tionnaire (BMQ), blood lipid levels, blood pressure, waist
circumference, body mass index (BMI), glucose blood
levels and a family history of cardiovascular diseases. If
indicated, preventive therapies (medication and lifestyle
interventions) are initiated and followed over time [1].
All patients referred to this screening program were
asked to participate in the MIRROR- trial. ‘Participants’
were patients who were willing to participate in the
intervention study and ‘non-participants’ were patients
who declined informed consent for the MIRROR trial.
Because adherence to medication may also differ
between responders and non- responders to surveys,
with responders having higher adherence levels [21] we
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divided the group of non-participants further. Retro-
spectively of the MIRROR trial, a letter was sent to all
non-participants for a different study not subject to this
paper. For this study, a signed informed consent was
requested from the non-participants. Non-responders
were patients who did not sign this letter. Responders
were patients who signed the informed consent letter.
We aimed to explore if the non-responding subgroup of
the non-participants differed from the responders with
respect to their level of medication adherence on the
basis of prior MMS® from the screening program.
Ethical approval
The Ethical Committee waived the need for a formal in-
formed consent for this study. The study was conducted
according to the good clinical practice protocol and we
used usual care data considering the research question
of this study. Data was anonymized according to the re-
search protocols of the Ethical Committee.
Outcomes
Participation or declining to participate to the RCT was
the independent variable in this study. Adherence to
medication and the beliefs about medication the
dependent variables. Adherence to cardiovascular medi-
cation was calculated by the MMS® [22–24]. It consists
of eight items aimed at measuring adherence. Each item
accounts for 0 or 1 in the case questions are answered
by no or yes respectively. Consequently, total MMS®
scores range between 0 and 8. These scores were divided
into three levels of adherence: low adherence (sum
score < 6), medium adherence (sum score 6 to < 8) and
high adherence (sum score of 8) [25]. To evaluate pa-
tients’ beliefs and perceptions about their medication,
BMQ [26] was used. This validated questionnaire pro-
vides information about the beliefs, perceived necessity
and concerns the patient has regarding their illness and
prescribed medication. There are five statements regard-
ing “necessity beliefs” and five regarding “concern
beliefs”. Patients indicated their degree of agreement
with each individual statement about the use of their
medicines on a five-point Likert scale. Thus, total scores
for the necessity and concerns scales could range from 5
to 25. The necessity– concerns differential (NCD) was
then calculated as the difference between necessity and
concerns scores and had a possible range of − 20 to 20
[19, 27]. To differentiate between patients on the basis
of their beliefs about the necessity of their medication
and their concerns about taking medication, the total
necessity and concern scores [5−25] were split at mid-
point (thus 5–12 was considered as low and 13 t/m 25
was considered as high). Patients were then classified
into four different categories: accepting (high necessity
and low concerns), ambivalent (high necessity and high
concerns), skeptical (high concerns and low necessity)
and indifferent (low concerns and low necessity) [28–
30].
From all patients the type of CVD (acute coronary
syndrome, myocardial infarction, peripheral arterial dis-
ease, an aneurysm of the aorta or TIA) was recorded.
Also, the following baseline and clinical characteristics
were collected: age, sex, level of education, employment
status, the country of origin and the type of cardiovascu-
lar medication used.
Data collection and timeline
Data were derived from the screening program. Data
were registered in a secure website which could only be
accessed by nurses involved in the screening program.
Within, on average, six weeks after the CVD-event,
baseline characteristics and the questionnaires were col-
lected for all patients as part of the screening program.
Statistical analyses
Data were analyzed and evaluated using SPSS version
22. Descriptive statistics (mean, median, standard devi-
ation) were used for all variables. A Mann-Whitney Test
was used to compare groups (participants and
non-participants) with the non parametric outcome, the
MMS®. Confounders were explored by performing a lo-
gistic linear test of all the characteristics in the case the
groups significantly differed (including the NCD). The
same Mann-Whitney test was performed to compare the
NCD between the groups. A logistic regression was used
to explore differences between (non) participants and
the four belief groups. The same statistical analyses were
performed for the responders and non-responders. A
Kruskal-Wallis test was performed to explore the rela-
tionship between the NCD and the MMS® for all groups.
Results
In total, 900 patients with a new cardiovascular event be-
tween October 2011 and October 2013 were eligible for
participation into the MIRROR trial. Of these, 419 agreed
and 481 refused participation. Of all the non-participants
who received a letter for another study, 220 did not re-
spond. Consequently, 261 non-participants were classified
as responders (Fig. 1).
Patient characteristics
The total cohort (participants and non-participants) had a
mean age of 62 years and was predominantly male (67%).
Participants significantly differed from non-participants
with respect to age (61 years versus 63 years, p = 0.001),
male sex (71% versus 58%, p = 0.001), systolic blood pres-
sure (136mmHg versus 142mmHg, p = 0.001). Partici-
pants were more frequently diagnosed with an acute
coronary syndrome (36% versus 16%, p < 0.001]), were
Sieben et al. BMC Medical Research Methodology           (2019) 19:95 Page 3 of 9
using more beta blocking agents or agents acting on
the renin-angiotensin system (58% versus 46% p = 0.001
and 59% versus 44% p = 0.001, respectively), and were
using more lipid lowering medication (94% versus
82%, p < 0.001). Among the non-participants, responders
were older (64 versus 60 years, p = 0.002) and used more
agents acting on the renin-angiotensin system (48% versus
37%, p = 0.02) than non-responders (Tables 1 and 2).
Medication adherence
We did not observe differences in adherence measured
by the MMS® between both groups (p = 0.99). According
to the MMS® 19% of the participants was classified as
low adherers compared to 20% in the non-participants
group. Forty-six percent of the participants and 44% of
the non-participants were classified as medium adherers,
whereas 36 and 37% were classified as high adherers,
respectively. There were no differences in adherence
according to the MMS® between responders and
non-responders (p = 0.47). In both the responders and
non-responders group, 36% scored high on adherence.
Sixteen percent of the responders were low adherent com-
pared to 24% in the non-responder group. Forty-eight
percent of the responder group scored a medium adher-
ence and 41% of the non-responders. Compared to study
participation all characteristics that significantly differed
between both groups were separately analyzed by a logistic
regression analyses. None of the variables significantly
influenced the association between study participation
and adherence according to the MMS® (Tables 3 and 4).
Beliefs about medication
Based on the BMQ the necessity concerns differential
(NCD) was 3.8 among participants compared to 3.4
among non-participants (p = 0.13). Of all the participat-
ing and non-participating patients 26% were in the
accepting group, 67% in the ambivalent group, 3% in the
skeptical and 4% in the indifferent group. No differences
Fig. 1 Participants, non-participants,responders and non responders and MMS and BMQ
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were observed between the two groups (p = 0.23). The
mean score of the NCD in the responders and
non-responders groups was 3.6 and 3.1 respectively (p =
0.21). Among the non-responders 24% were in the
accepting group, 61% in the ambivalent group, 6% in the
skeptical group and 9% in the indifferent group. For the
responders this was 27, 72, 2 and 0% respectively.
Differences between both groups were statistically
significant (p < 0.01). Logistic regression analysis on
NCD did not significantly influence the association
between study participation and adherence according
to the MMS®.
Table 1 Differences in patient characteristics between participants and non participants in a RCT-trial on adherence
Participants [n = 419] Non-participants [n = 481] P-value
Age [mean, ±SD) 60.5 [±10] 63 [11] 0.001
Gender (N [%])
Male 296 [7] 279 [58] < 0.001
Female 123 [29 202 [42]
Education level (N[%]) < 0.001
Primary 66 [18] 141 [31]
Secondary 185 [49] 180 [39]
University 124 [33] 140 [30]
Labour (N[%]) 0.08
Paid labour 137 [37] 123 [27]
Unemployed 98 [26.3] 138 [30]
Retired 138 [37] 199 [43.3]
Country of origin is the Netherland (N[%]) 0.66
Yes 327 [90] 398 [86]
No 37 [10] 64 [14]
Reason referral (N[%]) < 0.001
acute coronary syndrome 150 [36] 79 [16]
peripheral arterial disease 71 [17] 101 [21]
troke/TIA 198 [47] 301 [63]
Blood pressure (mmHg; mean ± SD) < 0.001
Systolic 136 [±18] 142 [±20] 0.23
Diastolic 77 [±11] 78 [±11]
Body Mass Index (mean ± SD) 27 [±4] 26 [±4] 0.30
Waist (mean ± SD)
Male 99.5 [±9] 98.4 [±12] 0.10
Female 92 [±14] 90 [±13] 0.07
Lipids (mmol/ltr, mean SD)
Totaal cholesterol 4.5 [±1.1] 4.6 [±1] 0.7
Triglyceriden 1.8 [±1] 1.7 [±1] 0.01
HDL 1.2 [±0.3] 1.2 [±0.3] 0.002
LDL 2.5 [±0.9] 2.6 [±0.9] 0.66
Medication (N [%])
Antithrombotic agents [ATC B01] 404 [98] 461 [98] 0.78
Diuretics [ATC C03] 109 [26] 135 [29] 0.44
Beta Blocking agents [ATC C07] 239 [58] 218 [46] 0.001
Calcium channel blockers [ATCC08] 65 [16] 72 [15] 0.86
Agents acting on [..] system [ATC C09] 244 [59] 206 [44] 0.001
Lipid modifying agents [ATC C10] 387 [94] 384 [82] < 0.001
Sieben et al. BMC Medical Research Methodology           (2019) 19:95 Page 5 of 9
Discussion
To our knowledge this is the first study exploring the
differences in medication adherence in patients who did
or did not consent to participate in an RCT evaluating
the effect of an intervention to improve medication
adherence. Our study showed that patients willing to
participate in an RCT evaluating the effect of an interven-
tion to improve medication adherence, have a comparable
adherence level to patients who declined participation.
Even by further exploring the non-participant group in
Table 2 Differences in patient characteristics between responders and non-responders
responder [n = 206] Non-responder [n = 220] P-value
Age (mean ± SD) 64 [10] 60 [12] 0.002
Gender (N [%])
Male 120 [58] 129 [59] 0.93
Female 86 [42] 91 [41]
Education level (N[%])
Primary 52 [26] 67 [32] 0.43
Secondary 80 [41] 81 [39]
University 66 [33] 62 [29]
Labour (N [%])
Paid labour 49 [25] 68 [33] 0.08
Unemployed 55 [28] 64 [31]
Retired 94 [47] 77 [36]
Country of origin is the Netherlands(N[%])
Yes 174 [88] 181 [86] 0.62
No 24 [12] 29 [14]
Reason referral (N[%]) 0.89
acute coronary syndrome 34 [16] 37 [17]
peripheral arterial disease 47 [23] 46 [21]
stroke/TIA 125 [61] 137 [62]
Blood pressure (mmHg; mean ± SD)
Systolic 140 [±19] 142 [±20] 0.30
Diastolic 78 [±11] 79 [±10] 0.23
Body Mass Index (mean ± SD) 26 [±4] 26 [±4] 0.22
Waist (mean ± SD)
Male 97 [±11] 99 [±12] 0.16
Female 91 [±13] 89 [±13] 0.36
Lipids (mmol/ltr; mean ± SD)
Totaal cholesterol 4.6 [±1] 4.6 [±0.9] 0.73
Triglyceriden 1.7 [±1] 1.7 [±0.9] 0.01
HDL 1.3 [±0.3] 1.2 [±0.3] 0.06
LDL 2.5 [±0.9] 2.6 [±0.9] 0.78
Medication(N [%])
Antithrombotic agents [ATC B01] 196 [97] 213 [98] 0.27
Diuretics [ATC C03] 62 [31] 56 [26] 0.28
Beta Blocking agents [ATC C07] 93 [46] 96 [44] 0.74
Calcium channel blockers [ATCC08] 30 [15] 34 [16] 0.80
Agents acting on [..] system [ATC C09] 98 [48] 80 [37] 0.02
Lipid modifying agents [ATC C10] 166 [82] 173 [80] 0.59
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responders and non-responders, we did not observe differ-
ences in adherence between the groups. Consequently, the
results of this study suggest that a population representative
in adherence level participated in an RCT evaluating the ef-
fect of an intervention to improve medication adherence.
Previous studies suggested that patients not participat-
ing in RCTs to improve medication adherence have a
different pre-existing adherence level from patients who
participate [10–14]. This was supported by the observed
differences in adherence levels between these RCTs and
observational studies [10–14]. Typically, adherence
levels among patients in RCTs were higher than in
observational studies. Although not different among
participants and non-participants, adherence in this
study was also high. An explanation for the high adher-
ence rate in both groups could be that we started
inclusion for the RCT within six weeks after the car-
diovascular event. For cardiovascular patients who
just had an event, the need for adherent behaviour is
emerging [31, 32]. Yet, as the event fades and symp-
toms subside, adherence levels can also decline [33].
Research with a long follow up is needed to establish
if there will be a difference in adherence between par-
ticipants and non-participants over time.
In all groups, we observed significant differences in
patient characteristics. Compared to non-participants,
participants were younger and more were highly edu-
cated. This was also observed among responders and
non-responders. These are known as prognostic charac-
teristics for patients who are willing to participate in a
clinical trial [15] and for a high adherence level [34, 35].
Although the relationship between socio-demographic
variables and adherence is mainly weak and inconsistent
[34, 36, 37] it was expected that these characteristics
could have been an explanation for the assumed higher
adherence rates in the participant groups. However, we
could not support this hypothesis. Also, next to the high
adherence rate, a high mean NCD score was present in
all groups. This only confirmed the adherent behaviour
in both groups [19]. It is also congruent with earlier
studies showing that medication beliefs can be a more
powerful predictor of medication adherence than clinical
and socio-demographic factors [19, 38]. However, we did
not observe a relationship between NCD and trial
Table 3 Differences participants and non-participants in adherence and beliefs about medication
Totaal Non-participants Participants P-value
Adherence according to the MMS N [%] 0.99
Low adherence 119 [19] 49 [20] 70 [19]
Medium adherence 279 [45] 109 [44] 170 [46]
High adherence 222 [36] 90 [36] 132 [35]
NCD mean [SD] 3.65[±4.8] 3.4 [±5] 3.8 [±4.9] 0.13
Belief Groups [N%] 0.23
Accepting 160 [26] 61 [24] 100 [27]
Ambivalent 418 [67] 165 [67] 255 [68]
Sceptical 19 [3] 10 [4] 9 [2]
Indifferent 23 [4] 13 [10] 10 [3]
Table 4 Differences responders and non-responders in adherence and belief about medication
Totaal Non-responders Responders P-value
Adherence according to the MMS N [%] 0.47
Low adherence 43 [20] 24 [24] 19 [16]
Medium adherence 99 [45] 41 [40] 58 [48]
High adherence 79 [36] 36 [36] 43 [36]
NCD mean [SD] 3.6 [±4.9] 3.1 [±5] 4 [±4.9] 0.17
Belief Groups [N%] 0.001
Accepting 56 [25] 24 [24] 32 [27]
Ambivalent 148 [67] 62 [61] 86 [72]
Sceptical 8 [4] 6 [6] 2 [2]
Indifferent 10 [4] 10 [9] 0 [0]
Sieben et al. BMC Medical Research Methodology           (2019) 19:95 Page 7 of 9
participation. We did observe a significant difference in the
beliefs about medication groups in the (non) responder
groups. More patients of the non-responder group were
also in the indifferent and skeptical group. Non-responders
of surveys are known for more negative evaluations of
healthcare [39]. This could be associated with higher
concern beliefs in medication as these are partly influenced
by the prescriber-patient relationship in healthcare [40].
The number of patients who differed in these groups was
very small and the NCD did not differ. More research is
needed to draw any conclusions on this point.
This study had some limitations. We had to deal with
missing data especially in the self reported question-
naires BMQ and MMS®. There were fewer missing in
the participants group compared to the non-participants
group. The questionnaires were just implemented in the
screening program. As the questionnaires were also part
of the MIRROR trial, more attention could have been paid
to participants for documenting these questionnaires. So
there were more patients in the non-participant group
who did not fill out the MMS®. These patients could very
well be non-adherent [21]. There are different methods
available to measure adherence. Each method has advan-
tages and disadvantages. The MMS® [22, 24, 41] is a
validated questionnaire that can be easily applied to large
populations. As MMS® is a subjective measure, adherence
levels may be higher than what is expected in real life.
Refill data from the out-patient pharmacy on the other
hand has been used extensively to provide insight into
drug acquisition and dispensing [42]. However, to use the
pharmacy refill data we need an informed consent from
patients. This study however used data from patients
collected only in standard care because we wanted to
include patients who declined participation in a RCT.
Other methods, such as MEMS or pill count, seem to in-
fluence patient’s behavior through direct confrontation.
Moreover, application of MEMS is relatively expensive, es-
pecially when applied in standard care [42]. The BMQ
was used because, to our knowledge, is the only vali-
dated questionnaire that evaluates patients’ beliefs, ne-
cessity and concerns the patient has according to his
illness and prescribed medication. This in contrast to
other validated adherence questionnaires that measure
specific medication-taking behavior of patients [26, 43].
The high NCD score confirmed the prediction of adherent
behaviour in both groups [19, 38] .
Conclusion
This study showed no differences in medication
adherence between participants and non-participants
prior to the inclusion of the MIRROR trial. A represen-
tative group seems to have participated in this random-
ized controlled trial designed to improve medication
adherence [20].
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